

SUBSTANCE OF THE INTERVIEW

On July 17, 2007, David Osborne, attorney for the Applicants, and Examiner Ghali held a telephone interview regarding the current rejections for the present application. U.S. Patent No. 6,352,715 (hereinafter “the ‘715 patent”) and Chinese Patent No. 1,111,987 (hereinafter “the ‘987 patent”) were discussed. Specifically, the Applicants contend that the cited art does not provide a sustain blood level of huperzine. Examiner Ghali suggested that the Applicants amend the claims to require a duration for sustaining the required blood levels, provide comparative data from the present invention and the delivery achieved with the patches of the cited art, and then submit a declaration of the findings with a supplemental reply for consideration.